Form 4: Lexeo CTO Sells Shares for Tax Obligations

Lexeo Therapeutics' Chief Technical Officer, Jose Manuel Otero, sold a portion of his common stock to cover tax obligations following an RSU vesting.

Summary

• Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, Inc. (LXEO), reported transactions involving the company's common stock.
• On October 15, 2025, Otero acquired 5,940 shares of common stock at a price of $0, likely due to the vesting of Restricted Stock Units (RSUs).
• Following this acquisition, Otero's beneficial ownership increased to 66,312 shares.
• On October 17, 2025, Otero disposed of 2,091 shares of common stock at a weighted average price of $8.935 per share.
• Additionally, on October 17, 2025, Otero disposed of another 24 shares of common stock at a weighted average price of $9.561 per share.
• Both sales on October 17, 2025, were executed to cover tax obligations associated with the release of RSUs.
• After these transactions, Otero's direct beneficial ownership stands at 64,197 shares, which includes 49,687 RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves insider selling, the explicit reason provided (to cover tax obligations on RSU vesting) is a routine and expected event, not typically indicative of a negative outlook on the company's future.

Positives

• The acquisition of 5,940 shares on October 15, 2025, indicates the vesting of Restricted Stock Units, reflecting continued equity compensation for the Chief Technical Officer.

Negatives

• The sale of 2,115 shares by a key executive, even for tax purposes, represents a reduction in insider holdings.

Risks

• While the sales were for tax obligations, any insider selling could be misinterpreted by the market as a lack of confidence, potentially leading to negative sentiment.

Stakeholder Impact

• Shareholders: The sale reduces the Chief Technical Officer's direct holdings, but the reason for the sale (tax obligations) is common and generally not a cause for concern regarding management's confidence.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to RSU vesting and subsequent tax-related sales. It does not provide sufficient information to warrant a change in investment recommendation. The sales are for tax purposes, which is a common occurrence and not typically a signal of a change in the executive's outlook on the company. Investors should 'hold' and look for broader financial and operational updates for investment decisions.

Keywords

Lexeo Therapeutics, LXEO, Insider Trading, Form 4, Jose Manuel Otero, Chief Technical Officer, Common Stock, Restricted Stock Units, RSU Vesting, Tax Obligations